阿卡波糖联合二甲双胍对糖耐量减低冠心病患者的干预作用  

Effect of acarbose and metformin treatment in patients with coronary heart disease accompanied by impaired glucose tolerance

作　　者：李岩[1,2] 孙晓斐[2] 丛培玲[2] 徐勤成[2] 魏子秀[2] 

机构地区：[1]济南大学山东省医学科学院医学与生命科学学院,山东济南250062 [2]济宁医学院附属济宁市第一人民医院,山东济宁272011

出　　处：《济宁医学院学报》2013年第1期28-30,33,共4页Journal of Jining Medical University

摘　　要：目的探讨阿卡波糖联合二甲双胍对合并糖耐量异常的冠心病患者心血管意外的影响。方法选取经冠状动脉造影诊断为冠心病且合并糖耐量异常的患者324例,随机分为阿卡波糖组、二甲双胍组、联合用药组及对照组,每组各81例,其中对照组仅给予基础治疗,其余3组均在基础治疗基础上给予相应药物治疗。结果经6个月随访,各药物治疗组心血管意外发生率均明显低于对照组(P<0.05),而药物治疗组之间心血管意外发生率无明显差异(P>0.05)。结论对合并糖耐量异常的冠心病患者应用阿卡波糖联合二甲双胍治疗可显著减少患者心血管意外的发生,而联合用药与单一用药之间对患者心血管意外的影响无明显差异。Objective To evaluate the effect of small dose of metformin and acarbose on cardiovascular events in patients with coronary heart disease combined with impaired glucose tolerance. Methods It was selected bycoronary angiography confirmed 324 cases of patients of coronary heart disease merged with impaired glucose tolerance. Randomly they were divided into acarbose, metformin group, the combined treatment group and the controlgroup,81 cases in each group. The control group were given basic treatment,and the remaining three groups were given drug treatment on the basis of the basic treatment.Results After 6 months of follow-up, the drug treatmentgroup cardiovascular events were significantly lower than the control group（P〈0.05）. The incidence of cardiovascular events was no significant difference between the drug treatment group（P〉0.05）.Conclusion Acarbose andmetformin Treatment can significantly reduce the incidence of cardiovascular events in patients of coronary heart disease merged with impaired glucose tolerance. Impact on cardiovascular events in patients is no significant differ-ence between the combination therapy with a single drug.

关 键 词：阿卡波糖 二甲双胍 糖耐量异常 冠状动脉粥样硬化性心脏病 

分 类 号：R541.5[医药卫生—心血管疾病]